On May 27, 2019 Medivir AB (Nasdaq Stockholm: MVIR) reported that the company will participate at the Redeye Pre-ASCO Seminar in Stockholm. The presentation will take place at 9.15am on Tuesday, May 28, 2019 (Press release, Medivir, MAY 27, 2019, View Source [SID1234536589]). Dr. Uli Hacksell, CEO of Medivir, will present the latest development and the company´s future.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available via Medivirs website; www.medivir.com.

For further information, please contact:

Uli Hacksell
CEO, Medivir AB
mobile: +46(0)73-125-0615.